Company news
Organogenesis Holdings Inc. (NASDAQ:ORGO) news
Every Organogenesis Holdings Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Chall...
July 27, 2026
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
July 9, 2026
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
July 6, 2026
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
May 7, 2026
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
April 28, 2026
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
April 6, 2026
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
April 6, 2026
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
February 26, 2026
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
February 19, 2026
Organogenesis Announces Initiation of Biologics License Application for ReNu®
December 23, 2025
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
December 15, 2025
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
November 6, 2025
Organogenesis Applauds CMS’s Significant Step In Payment Reform
November 3, 2025
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
October 1, 2025
Organogenesis Provides Update on Second Phase 3 ReNu® Study
September 25, 2025
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
August 27, 2025
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
August 7, 2025
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
July 22, 2025
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate P...
July 15, 2025
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
May 8, 2025
Organogenesis Supports CMS’ Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with...
April 11, 2025
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
April 7, 2025
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
February 27, 2025
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
January 27, 2025
Organogenesis Expands Manufacturing Capacity to Support Future Growth
November 22, 2024
Organogenesis Commends Final LCDs
November 15, 2024
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock
November 12, 2024
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
November 12, 2024
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
November 11, 2024
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
October 16, 2024
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic F...
October 1, 2024
Organogenesis Shares ReNu® Program Update
August 8, 2024
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
August 8, 2024
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
July 15, 2024
Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference
June 6, 2024
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
May 9, 2024
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
May 2, 2024
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
April 16, 2024
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
April 3, 2024
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
February 29, 2024
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 12, 2024
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024
February 8, 2024
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
November 9, 2023
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
October 5, 2023
Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS
September 28, 2023
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 6, 2023
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
August 9, 2023
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023
July 10, 2023
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
May 10, 2023